More than 75% of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses, 12 additional patients had stable disease and seven had progressive disease. Of the four patients with partial responses, three are continuing on study, including one patient who has been receiving treatment for more than seven months.
SGN-35 has been generally well-tolerated and the maximum tolerated dose has not yet been defined. The majority of adverse events were Grade 1 and 2, and are consistent with antibody administration. Dose-escalation has continued to 2.7 milligrams per kilogram (mg/kg).
Clay Siegall, president and CEO of Seattle Genetics, said: “These data not only demonstrate the therapeutic potential of SGN-35 in the treatment of Hodgkin lymphoma, but also underscore the impact that our antibody-drug conjugate (ADC) technology can have in empowering antibodies for the treatment of cancer. Based on these encouraging data, we are continuing with dose-escalation and planning future studies with SGN-35 to optimize dose and schedule, both as a single-agent and in combination with other agents.”